• Login
    View Item 
    •   UMB Digital Archive
    • UMB Open Access Articles
    • UMB Open Access Articles
    • View Item
    •   UMB Digital Archive
    • UMB Open Access Articles
    • UMB Open Access Articles
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of UMB Digital ArchiveCommunitiesPublication DateAuthorsTitlesSubjectsThis CollectionPublication DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Statistics

    Display statistics

    Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Author
    Ramsey, Laura B
    Ong, Henry H
    Schildcrout, Jonathan S
    Shi, Yaping
    Tang, Leigh Anne
    Hicks, J Kevin
    El Rouby, Nihal
    Cavallari, Larisa H
    Tuteja, Sony
    Aquilante, Christina L
    Beitelshees, Amber L
    Lemkin, Daniel L
    Blake, Kathryn V
    Williams, Helen
    Cimino, James J
    Davis, Brittney H
    Limdi, Nita A
    Empey, Philip E
    Horvat, Christopher M
    Kao, David P
    Lipori, Gloria P
    Rosenman, Marc B
    Skaar, Todd C
    Teal, Evgenia
    Winterstein, Almut G
    Owusu Obeng, Aniwaa
    Salyakina, Daria
    Gupta, Apeksha
    Gruber, Joshua
    McCafferty-Fernandez, Jennifer
    Bishop, Jeffrey R
    Rivers, Zach
    Benner, Ashley
    Tamraz, Bani
    Long-Boyle, Janel
    Peterson, Josh F
    Van Driest, Sara L
    Show allShow less

    Date
    2020-12-14
    Journal
    JAMA Network Open
    Publisher
    American Medical Association
    Type
    Article
    
    Metadata
    Show full item record
    See at
    https://doi.org/10.1001/jamanetworkopen.2020.29411
    Abstract
    Importance: Genotype-guided prescribing in pediatrics could prevent adverse drug reactions and improve therapeutic response. Clinical pharmacogenetic implementation guidelines are available for many medications commonly prescribed to children. Frequencies of medication prescription and actionable genotypes (genotypes where a prescribing change may be indicated) inform the potential value of pharmacogenetic implementation. Objective: To assess potential opportunities for genotype-guided prescribing in pediatric populations among multiple health systems by examining the prevalence of prescriptions for each drug with the highest level of evidence (Clinical Pharmacogenetics Implementation Consortium level A) and estimating the prevalence of potential actionable prescribing decisions. Design, Setting, and Participants: This serial cross-sectional study of prescribing prevalences in 16 health systems included electronic health records data from pediatric inpatient and outpatient encounters from January 1, 2011, to December 31, 2017. The health systems included academic medical centers with free-standing children's hospitals and community hospitals that were part of an adult health care system. Participants included approximately 2.9 million patients younger than 21 years observed per year. Data were analyzed from June 5, 2018, to April 14, 2020. Exposures: Prescription of 38 level A medications based on electronic health records. Main Outcomes and Measures: Annual prevalence of level A medication prescribing and estimated actionable exposures, calculated by combining estimated site-year prevalences across sites with each site weighted equally. Results: Data from approximately 2.9 million pediatric patients (median age, 8 [interquartile range, 2-16] years; 50.7% female, 62.3% White) were analyzed for a typical calendar year. The annual prescribing prevalence of at least 1 level A drug ranged from 7987 to 10 629 per 100 000 patients with increasing trends from 2011 to 2014. The most prescribed level A drug was the antiemetic ondansetron (annual prevalence of exposure, 8107 [95% CI, 8077-8137] per 100 000 children). Among commonly prescribed opioids, annual prevalence per 100 000 patients was 295 (95% CI, 273-317) for tramadol, 571 (95% CI, 557-586) for codeine, and 2116 (95% CI, 2097-2135) for oxycodone. The antidepressants citalopram, escitalopram, and amitriptyline were also commonly prescribed (annual prevalence, approximately 250 per 100 000 patients for each). Estimated prevalences of actionable exposures were highest for oxycodone and ondansetron (>300 per 100 000 patients annually). CYP2D6 and CYP2C19 substrates were more frequently prescribed than medications influenced by other genes. Conclusions and Relevance: These findings suggest that opportunities for pharmacogenetic implementation among pediatric patients in the US are abundant. As expected, the greatest opportunity exists with implementing CYP2D6 and CYP2C19 pharmacogenetic guidance for commonly prescribed antiemetics, analgesics, and antidepressants.
    Keyword
    genotype-guided prescribing
    Drug Prescriptions
    Pediatrics
    Pharmacogenetics
    Identifier to cite or link to this item
    http://hdl.handle.net/10713/14660
    ae974a485f413a2113503eed53cd6c53
    10.1001/jamanetworkopen.2020.29411
    Scopus Count
    Collections
    UMB Open Access Articles

    entitlement

    Related articles

    • Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy Users.
    • Authors: Chanfreau-Coffinier C, Hull LE, Lynch JA, DuVall SL, Damrauer SM, Cunningham FE, Voight BF, Matheny ME, Oslin DW, Icardi MS, Tuteja S
    • Issue date: 2019 Jun 5
    • Retrospective Review of Pharmacogenetic Testing at an Academic Children's Hospital.
    • Authors: Roberts TA, Wagner JA, Sandritter T, Black BT, Gaedigk A, Stancil SL
    • Issue date: 2021 Jan
    • Use of antidepressants with pharmacogenetic prescribing guidelines in a 10-year depression cohort of adult primary care patients.
    • Authors: Jessel CD, Mostafa S, Potiriadis M, Everall IP, Gunn JM, Bousman CA
    • Issue date: 2020 Sep
    • Opportunity for Genotype-Guided Prescribing Among Adult Patients in 11 US Health Systems.
    • Authors: Hicks JK, El Rouby N, Ong HH, Schildcrout JS, Ramsey LB, Shi Y, Anne Tang L, Aquilante CL, Beitelshees AL, Blake KV, Cimino JJ, Davis BH, Empey PE, Kao DP, Lemkin DL, Limdi NA, P Lipori G, Rosenman MB, Skaar TC, Teal E, Tuteja S, Wiley LK, Williams H, Winterstein AG, Van Driest SL, Cavallari LH, Peterson JF, IGNITE Pharmacogenetics Working Group.
    • Issue date: 2021 Jul
    • Evaluation of population-level pharmacogenetic actionability in Alabama.
    • Authors: Davis BH, Williams K, Absher D, Korf B, Limdi NA
    • Issue date: 2021 Nov
    DSpace software (copyright © 2002 - 2022)  DuraSpace
    Quick Guide | Policies | Contact Us | UMB Health Sciences & Human Services Library
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.